Paragon 28, Inc. FNA
We take great care to ensure that the data presented and summarized in this overview for Paragon 28, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FNA
View all-
Mvm Partners, LLC Boston, MA10.9MShares$85.1 Million80.25% of portfolio
-
First Light Asset Management, LLC Edina, MN3.8MShares$29.7 Million3.67% of portfolio
-
Black Rock Inc. New York, NY3.48MShares$27.2 Million0.0% of portfolio
-
Braidwell LP Stamford, CT3.37MShares$26.3 Million1.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.11MShares$16.5 Million0.0% of portfolio
-
Bleichroeder LP New York, NY1.76MShares$13.8 Million6.75% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.31MShares$10.3 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.2MShares$9.38 Million0.01% of portfolio
-
State Street Corp Boston, MA1.15MShares$8.97 Million0.0% of portfolio
-
Degroof Petercam Asset Management Brussels, C9974KShares$7.62 Million0.14% of portfolio
Latest Institutional Activity in FNA
Top Purchases
Top Sells
About FNA
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
Insider Transactions at FNA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 17
2024
|
Quentin S. Blackford |
BUY
Grant, award, or other acquisition
|
Direct |
15,906
+23.93%
|
-
|
May 17
2024
|
Alf Grunwald |
BUY
Grant, award, or other acquisition
|
Direct |
15,906
+23.45%
|
-
|
May 17
2024
|
Thomas P Schnettler |
BUY
Grant, award, or other acquisition
|
Direct |
15,906
+26.1%
|
-
|
May 17
2024
|
Kristina Wright |
BUY
Grant, award, or other acquisition
|
Direct |
15,906
+29.15%
|
-
|
May 17
2024
|
Meghan Scanlon |
BUY
Grant, award, or other acquisition
|
Direct |
15,906
+27.42%
|
-
|
May 17
2024
|
Stephen N. Oesterle |
BUY
Grant, award, or other acquisition
|
Direct |
15,906
+28.34%
|
-
|
May 17
2024
|
B Kristine Johnson |
BUY
Grant, award, or other acquisition
|
Direct |
15,906
+25.15%
|
-
|
Mar 15
2024
|
Albert Da Costa |
BUY
Open market or private purchase
|
Indirect |
28,000
+0.52%
|
$252,000
$9.12 P/Share
|
Mar 08
2024
|
Albert Da Costa |
BUY
Grant, award, or other acquisition
|
Direct |
166,924
+20.6%
|
-
|
Mar 08
2024
|
Erik E Mickelson Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,455
+28.92%
|
-
|
Mar 08
2024
|
Robert S Mc Cormack |
BUY
Grant, award, or other acquisition
|
Direct |
71,483
+36.12%
|
-
|
Mar 08
2024
|
Matthew Jarboe Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
98,454
+19.86%
|
-
|
Mar 08
2024
|
Stephen Deitsch Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
108,346
+33.14%
|
-
|
Feb 28
2024
|
Albert Da Costa |
SELL
Payment of exercise price or tax liability
|
Direct |
9,470
-1.95%
|
$113,640
$12.15 P/Share
|
Feb 28
2024
|
Erik E Mickelson Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
924
-3.94%
|
$11,088
$12.15 P/Share
|
Feb 28
2024
|
Stephen Deitsch Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,613
-3.17%
|
$43,356
$12.15 P/Share
|
Feb 28
2024
|
Matthew Jarboe Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,282
-1.09%
|
$39,384
$12.15 P/Share
|
Dec 01
2023
|
Kristina Wright |
SELL
Payment of exercise price or tax liability
|
Direct |
1,888
-7.66%
|
$20,768
$11.7 P/Share
|
Nov 10
2023
|
Albert Da Costa |
BUY
Open market or private purchase
|
Indirect |
30,500
+0.57%
|
$244,000
$8.51 P/Share
|
Oct 21
2023
|
Erik E Mickelson Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,020
-4.24%
|
$9,180
$9.49 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 627K shares |
---|---|
Open market or private purchase | 58.5K shares |
Other acquisition or disposition | 130K shares |
Payment of exercise price or tax liability | 51.6K shares |
---|---|
Open market or private sale | 13.7K shares |
Other acquisition or disposition | 2.9M shares |